Ketorolac
Active ingredient · 2 therapeutic classes
- Drug class
- Acetic Acid Derivatives and Related Substances
- Availability
- Prescription only
- Routes
- Oral, Ophthalmic, Intramuscular, Intravenous
- Markets covered
- 2
- Products on record
- 18
Overview
Plain-language summary, compiled from the cited regulatory records
Ketorolac is an active ingredient belonging to the drug class of acetic acid derivatives and related substances [1].
Ketorolac tromethamine is indicated for the short-term management of moderately severe acute pain that requires analgesia at the opioid level, typically in a postoperative setting [1]. The duration of use should not exceed 5 days [1]. When considering ketorolac, it is important to carefully evaluate its potential benefits and risks alongside other treatment options [1]. The lowest effective dose should be used for the shortest duration necessary to achieve individual patient treatment goals [1].
This medication is sold under several brand names [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 14 | April 5, 2026 |
| CA Canada | Health Canada | 4 | March 22, 2025 |
USUnited States· FDA
14 products
Uses
INDICATIONS AND USAGE
Carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ).
Acute Pain in Adult Patients Ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary.
The total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see WARNINGS , PRECAUTIONS , DOSAGE AND ADMINISTRATION , and ADVERSE REACTIONS ).
CACanada· Health Canada
4 products
Uses
Intramuscular injection of Ketorolac Tromethamine Injection USP (ketorolac tromethamine injection) is indicated for: • the short-term management (not to exceed 2 days) of moderate to severe acute pain, including pain following major abdominal, orthopedic and gynecological operative procedures.
The total combined duration of intramuscular and oral treatment should not exceed 5 days. For patients with an increased risk of developing CV and/or GI adverse events, other management strategies that do NOT include the use of NSAIDs should be considered first (see
How to take
Drug interactions
Known interactions involving Ketorolac. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 463. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 004588ba-e109-4a… · revised October 12, 2022 [PDF]
- [2]Health Canada (DPD) · 02239944 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.